JP2023530320A5 - - Google Patents

Info

Publication number
JP2023530320A5
JP2023530320A5 JP2022577341A JP2022577341A JP2023530320A5 JP 2023530320 A5 JP2023530320 A5 JP 2023530320A5 JP 2022577341 A JP2022577341 A JP 2022577341A JP 2022577341 A JP2022577341 A JP 2022577341A JP 2023530320 A5 JP2023530320 A5 JP 2023530320A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
methyl
carboxamide
oxopyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037160 external-priority patent/WO2021257420A1/en
Publication of JP2023530320A publication Critical patent/JP2023530320A/ja
Publication of JP2023530320A5 publication Critical patent/JP2023530320A5/ja
Pending legal-status Critical Current

Links

JP2022577341A 2020-06-17 2021-06-14 Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド Pending JP2023530320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040465P 2020-06-17 2020-06-17
US63/040,465 2020-06-17
PCT/US2021/037160 WO2021257420A1 (en) 2020-06-17 2021-06-14 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors

Publications (2)

Publication Number Publication Date
JP2023530320A JP2023530320A (ja) 2023-07-14
JP2023530320A5 true JP2023530320A5 (enExample) 2024-06-20

Family

ID=79268285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577341A Pending JP2023530320A (ja) 2020-06-17 2021-06-14 Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド

Country Status (10)

Country Link
US (1) US20230227405A1 (enExample)
EP (1) EP4167993A4 (enExample)
JP (1) JP2023530320A (enExample)
KR (1) KR20230026405A (enExample)
CN (1) CN115697327A (enExample)
AU (1) AU2021292062A1 (enExample)
BR (1) BR112022024476A2 (enExample)
CA (1) CA3180372A1 (enExample)
MX (1) MX2022015580A (enExample)
WO (1) WO2021257420A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230026404A (ko) 2020-06-17 2023-02-24 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
MX2023013147A (es) * 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
SMT202600064T1 (it) 2021-06-04 2026-03-09 Vertex Pharma Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256486A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
KR20260116140A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260116141A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료용 화합물 및 이의 고체 형태의 제조방법
KR20260118418A (ko) 2023-10-23 2026-07-30 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
AU2024393245A1 (en) 2023-12-07 2026-06-18 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
AU2025211735A1 (en) 2024-01-24 2026-07-16 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
KR20060073930A (ko) * 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
GB0514017D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
AP2013007331A0 (en) * 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
WO2014146111A2 (en) * 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
JP2018507900A (ja) * 2015-03-13 2018-03-22 アッヴィ・インコーポレイテッド （インダゾール−４−イル）ヘキサヒドロピロロピロロン及び使用方法

Similar Documents

Publication Publication Date Title
JP2024519487A5 (enExample)
RU2315041C2 (ru) Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения
RU2440330C2 (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
JP2005510500A5 (enExample)
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2019533694A5 (enExample)
JP2022544714A5 (enExample)
ME02532B (me) Jedinjenja beta-laktama supstituisana amidinom, njihovo dobijanje i upotreba kao antibakterijskih sredstava
JP2013544276A5 (enExample)
JPH05279337A (ja) Ａｉｄｓの治療に有用なｈｉｖプロテアーゼ阻害剤
JP2025160175A5 (enExample)
JP2020506171A5 (enExample)
JP2004538285A5 (enExample)
RU2019132254A (ru) Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
SI2961736T1 (en) Histone demethylase inhibitors
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
JP2005511543A5 (enExample)
JP2012502974A5 (enExample)
JP2014523400A (ja) 芳香族アミド類およびそれらの使用
JP2020511452A5 (enExample)
JP2024518792A5 (enExample)
JP2021535134A5 (enExample)
CA2550596A1 (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
JP2022519301A5 (enExample)